For the approximately 5,000 Americans diagnosed with amyotrophic lateral sclerosis (ALS) each year, finding answers can present a major challenge. To help these individuals and their families, The Tow Foundation has spent the last 15 years partnering with medical institutions dedicated to advancing ALS research and patient care.
Since 1987, The Eleanor and Lou Gehrig ALS Center at Columbia University has provided those with ALS and their families a personalized approach to patient care that fosters knowledge, understanding and hope. A longtime grantee partner, the ALS Center also empowers individuals to join the fight against ALS by integrating cutting edge research and clinical trials into patient care.
The Tow Foundation is also proud to partner with the Center for Genomics of Neurodegenerative Disease (CGND) at the New York Genome Center (NYGC). The goal of the CGND is to use whole genome sequencing to identify mutations that lead to neurodegenerative diseases like ALS. To do this, the NYGC takes a groundbreaking, collaborative approach, working with researchers from 38 institutions across the globe as well as organizations like Target ALS.
